Irritable Bowel Syndrome Clinical Trial
Official title:
Internet-delivered Exposure-based Cognitive Behavior Therapy for Pain-predominant Functional Gastrointestinal Disorders in Children and Adolescents: an Implementation Study.
Verified date | February 2019 |
Source | Karolinska Institutet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This open trial aims to evaluate feasibility and preliminary effectiveness of an internet-delivered CBT-program for children and adolescents with functional gastrointestinal disorders when implemented in regular care.
Status | Completed |
Enrollment | 68 |
Est. completion date | December 18, 2018 |
Est. primary completion date | June 17, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 17 Years |
Eligibility |
Inclusion Criteria: - Age 8-17 at date of inclusion. - Fulfilling Rome IV-criteria for irritable bowel syndrome, functional dyspepsia or functional abdominal pain with a written statement from patient's physician confirming a diagnosis. - Stable psychotropic medication for at least 1 month. Exclusion Criteria: - concurrent serious medical conditions. - a psychiatric diagnosis, judged to be a more important treatment target than the abdominal pain. - on-going structured psychological treatment. - absence from school exceeding an average of 2 days a week the last month is a cause for exclusion since high school absence demands more intensive interventions than can be offered in ICBT. - on-going abuse or severe parental psychiatric illness in the family. - since treatment format assumes normal reading and writing skills, pronounced language skill deficits and learning difficulties lead to exclusion from the study. - lack of regular internet-access. |
Country | Name | City | State |
---|---|---|---|
Sweden | Department of Clinical Neuroscience, Karolinska Institutet | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Parental responses to children´s symptom behavior (ARCS) | Change in parental responses from baseline to 10 weeks. | Baseline to 10 weeks. | |
Other | Parental responses to children´s symptom behavior (ARCS) | Change in parental responses from baseline to 3 months follow-up. | Baseline to 5 months. | |
Other | Parental responses to children´s symptom behavior (ARCS) | Change in parental responses from baseline to 6 months follow-up. | Baseline to 8 months. | |
Primary | Global gastrointestinal symptoms (CSI-24: subscale 7 items on GI-symptoms). | Change in global gastrointestinal symptoms from baseline to 10 weeks. | Baseline to 10 weeks. | |
Secondary | Pain intensity (Faces Pain rating scale) | Change in pain intensity from baseline to 10 weeks | Baseline to 10 weeks | |
Secondary | Pain intensity (Faces Pain rating scale) | Change in pain intensity from baseline to 3 months follow-up. | Baseline to 5 months. | |
Secondary | Pain intensity (Faces Pain rating scale) | Change in pain intensity from baseline to 6 months follow-up. | Baseline to 8 months. | |
Secondary | Global gastrointestinal symptoms (CSI-24: subscale 7 items on GI-symptoms). | Change in global gastrointestinal symptoms from baseline to 3 months follow-up. | Baseline to 5 months. | |
Secondary | Global gastrointestinal symptoms (CSI-24: subscale 7 items on GI-symptoms). | Change in global gastrointestinal symptoms from baseline to 6 months follow-up. | Baseline to 8 months. | |
Secondary | Gastrointestinal symptoms module (PedsQL Gastro) | Change in different dimensions of gastrointestinal symptoms (e.g. pain-related symptoms, nausea, bloating) from baseline to 10 weeks. | Baseline to 10 weeks | |
Secondary | Gastrointestinal symptoms module (PedsQL Gastro) | Change in different dimensions of gastrointestinal symptoms (e.g. pain-related symptoms, nausea, bloating) from baseline to 3 months follow up. | Baseline to 5 months. | |
Secondary | Gastrointestinal symptoms module (PedsQL Gastro) | Change in different dimensions of gastrointestinal symptoms (e.g. pain-related symptoms, nausea, bloating) from baseline to 6 months follow up. | Baseline to 8 months. | |
Secondary | Fear for symptoms (Visceral sensitivity index) | Change in fear for symptoms from baseline to 10 weeks. | Baseline to 10 weeks. | |
Secondary | Fear for symptoms (Visceral sensitivity index) | Change in fear for symptoms from baseline to 3 months follow-up. | Baseline to 5 months. | |
Secondary | Fear for symptoms (Visceral sensitivity index) | Change in fear for symptoms from baseline to 6 months follow-up. | Baseline to 8 months. | |
Secondary | Avoidant behavior (IBS-BRQ) | Change in avoidant behavior from baseline to 10 weeks. | Baseline to 10 weeks | |
Secondary | Avoidant behavior (IBS-BRQ) | Change in avoidant behavior from baseline to 3 months follow-up. | Baseline to 5 months. | |
Secondary | Avoidant behavior (IBS-BRQ) | Change in avoidant behavior from baseline to 6 months follow-up. | Baseline to 8 months. | |
Secondary | Quality of life (PedsQL) | Change in quality of life from baseline to 10 weeks. | Baseline to 10 weeks. | |
Secondary | Quality of life (PedsQL) | Change in quality of life from baseline to 3 months follow-up. | Baseline to 5 months. | |
Secondary | Quality of life (PedsQL) | Change in quality of life from baseline to 6 months follow-up. | Baseline to 8 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A |